AGL 39.15 Decreased By ▼ -0.85 (-2.13%)
AIRLINK 127.17 Decreased By ▼ -1.89 (-1.46%)
BOP 6.77 Increased By ▲ 0.02 (0.3%)
CNERGY 4.66 Increased By ▲ 0.17 (3.79%)
DCL 8.49 Decreased By ▼ -0.06 (-0.7%)
DFML 40.85 Increased By ▲ 0.03 (0.07%)
DGKC 82.00 Increased By ▲ 1.04 (1.28%)
FCCL 33.00 Increased By ▲ 0.23 (0.7%)
FFBL 73.34 Decreased By ▼ -1.09 (-1.46%)
FFL 11.72 Decreased By ▼ -0.02 (-0.17%)
HUBC 109.25 Decreased By ▼ -0.33 (-0.3%)
HUMNL 14.25 Increased By ▲ 0.50 (3.64%)
KEL 5.20 Decreased By ▼ -0.11 (-2.07%)
KOSM 7.45 Decreased By ▼ -0.27 (-3.5%)
MLCF 39.01 Increased By ▲ 0.41 (1.06%)
NBP 63.31 Decreased By ▼ -0.20 (-0.31%)
OGDC 192.31 Decreased By ▼ -2.38 (-1.22%)
PAEL 25.60 Decreased By ▼ -0.11 (-0.43%)
PIBTL 7.29 Decreased By ▼ -0.10 (-1.35%)
PPL 153.35 Decreased By ▼ -2.10 (-1.35%)
PRL 25.42 Decreased By ▼ -0.37 (-1.43%)
PTC 17.20 Decreased By ▼ -0.30 (-1.71%)
SEARL 77.81 Decreased By ▼ -0.84 (-1.07%)
TELE 7.51 Decreased By ▼ -0.35 (-4.45%)
TOMCL 33.18 Decreased By ▼ -0.55 (-1.63%)
TPLP 8.38 Decreased By ▼ -0.02 (-0.24%)
TREET 16.30 Increased By ▲ 0.03 (0.18%)
TRG 56.40 Decreased By ▼ -1.82 (-3.13%)
UNITY 27.54 Increased By ▲ 0.05 (0.18%)
WTL 1.36 Decreased By ▼ -0.03 (-2.16%)
BR100 10,476 Increased By 30.5 (0.29%)
BR30 31,021 Decreased By -168.2 (-0.54%)
KSE100 97,788 Decreased By -10.5 (-0.01%)
KSE30 30,487 Increased By 6.3 (0.02%)

French biotech AB Science hopes to win approval to sell its most promising drug as a treatment for digestive tract and pancreatic cancer as soon as 2014, its chief executive Alain Moussy said in an interview.
With enough cash to fund itself for the next three years, Moussy said AB Sciences was confident it would not have to seek a partner or buyer, while a quick approval for its potential cancer treatment masitinib would help guarantee its independence.
AB Science's progress with masitinib has helped its shares jump some 217 percent since the start of the year, by far the biggest riser on the CAC mid and small index, valuing it at close to 600 million euros ($762.66 million).
The Paris-listed group recently applied to the European Medicines Agency (EMA) to start selling masitinib, already used as veterinary drug, to treat pancreatic and digestive tract cancers in humans. It expects a decision by the end of 2013.

Copyright Reuters, 2012

Comments

Comments are closed.